Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Targovax ASA ( (GB:0RIS) ) has issued an announcement.
Circio Holding ASA announced a live webcast to present its first half 2025 financial results and recent in vivo data for its circVec platform technology. The webcast will provide insights into the company’s ongoing testing and optimization of circVec for AAV gene therapy, highlighting its strong performance and future experimental plans. This announcement underscores Circio’s commitment to advancing its circular RNA technology, potentially positioning it as a leader in nucleic acid medicine.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing circular RNA vector expression technology for next-generation nucleic acid medicine. Their proprietary circVec platform is designed for efficient biogenesis of multifunctional circRNA, with applications in genetic medicine, cell therapy, and chronic disease. The company also continues to develop its TG01 immuno-oncology program targeting RAS-mutated cancers.
Average Trading Volume: 721,059
Current Market Cap: NOK63.2M
See more data about 0RIS stock on TipRanks’ Stock Analysis page.